1) vascular-disrupting agents
肿瘤血管阻断制剂
1.
Based on the differece of the treatment machanisms and stages,two distinct groups of vascular-targeted therapies have evolved:antiangiogenic agents and vascular-disrupting agents.
根据作用机理及对血管抑制的阶段不同,肿瘤血管靶向治疗分为抗血管新生制剂和肿瘤血管阻断制剂。
3) vascular disrupting agents
血管阻断剂
4) Stomach neoplasms·Vasculogenic mimicry·Angiogenesis inhibitors
胃肿瘤·血管生成拟态·血管生成抑制剂
5) Alphastatin
肿瘤血管抑制肽
1.
Methods According to Alphastatin gene sequence in Gene Bank,double stranded cDNA of Alphastatin was gained by asymmetrical primer/template.
目的构建神经营养素(NT4)与肿瘤血管抑制肽Alphastatin融合基因的原核表达载体pBV220-NT4-Al。
6) Tumor vessel
肿瘤血管
1.
Objective To investigate the expression of hypoxia-inducible factor-1 alpha (HIF-1α)and iducible nitric oxide synthase (iNOS)in glioma,and the correlation between their and the formation of tumor vessel.
目的:探讨诱导型一氧化氮合酶(iNOS)、缺氧诱导因子-1α(HIF-1α)在人脑胶质瘤标本表达特点及其相关性;探讨HIF-1α和iNOS与肿瘤血管形成的相关性。
补充资料：血管紧张素转换酶抑制剂
血管紧张素转换酶抑制剂
converting enzyme inhibitor of angiotensin
能够抑制血管紧张素转换酶的活性、使血管紧张素Ⅰ不能转换成血管紧张素Ⅱ的物质，如替普罗肽(又称SQ20881）及卡托普利(又称SQ14225）。用于肾血管性高血压及高血压危象。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条